(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐 CAS#: 222631-44-9

(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐

生物活性靶点体外研究体内研究用途与合成方法 MSDS (2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐价格(试剂级) 上下游产品信息

中文名称	(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐
中文同义词	(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐;加利司韦盐酸盐;化合物 T10491L
英文名称	3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, monohydrochloride, (2S,3S,4R,5R)-
英文同义词	3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, monohydrochloride, (2S,3S,4R,5R)-;3,4-Pyrrolidinediol,2-(4-aMino-5H-pyrrolo[3,2-d]pyriMidin-7-yl)-5-(hydroxyMethyl)-, hydrochloride(1:1), (2S,3S,4R,5R)-;BCX 4430;(2S,3S,4R,5R)-2-(4-Amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3,4-pyrrolidinediol monohydrochloride;BCX-4430 (BCX4430;Galidesivir);BCX4430;GALIDESIVIR;GALIDESIVIR HYDROCHLORIDE (BCX 4430 HYDROCHLORIDE)
CAS号	222631-44-9
分子式	C11H16ClN5O3
分子量	301.73
EINECS号
相关类别
Mol文件	222631-44-9.mol
结构式

(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐性质

储存条件	Store at -20°C
水溶解性	Water : ≥ 41 mg/mL (135.88 mM)

(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐用途与合成方法

生物活性

Galidesivir (BCX4430) hydrochloride，一种腺苷类似物和直接作用的抗病毒药物，能破坏病毒 RNA 依赖的 RNA 聚合酶 (RdRp) 活性。Galidesivir hydrochloride 在体外对多种 RNA 病毒病原体具有活性，包括丝状病毒和新兴的感染因子，如 MERS-CoV、SARS-CoV 和 SARS-CoV-2。Galidesivir hydrochloride 对一些负义 RNA 病毒的 EC50 在 ~3 到 ~68 μM 之间。

靶点

RdRp inhibitor

体外研究

Cellular kinases phosphorylate Galidesivir (BCX4430) hydrochloride to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination.
Galidesivir hydrochloride effectively inhibits the infection of Vero cells with YFV. The EC ₅₀ determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM).

体内研究

Galidesivir (BCX4430) hydrochloride is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir hydrochloride has demonstrated pronounced efficacy.
Galidesivir hydrochloride (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF).

Animal Model:	Female Syrian golden hamsters (hamsters infected with YF virus)
Dosage:	4 mg/kg of body weight
Administration:	I.p.; twice daily for 7 days
Result:	Significantly improved the survival of hamsters infected with YFV.

安全信息

MSDS信息

(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐价格(试剂级)

更新日期	产品编号	产品名称	CAS号	包装	价格
2024/01/25	HY-18649A	(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐 Galidesivir	222631-44-9	1mg	2000元
2024/01/25	HY-18649A	(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐 Galidesivir	222631-44-9	5mg	6000元

(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐